Market Overview

Aegis Capital Initiates Coverage on Sinovac Biotech, Ltd. at Hold, Announces $2.50 PT

Share:

Latest Ratings for SVA

DateFirmActionFromTo
Mar 2014Morgan StanleyUpgradesOverweight
Nov 2013Aegis CapitalMaintainsBuy
Aug 2013Aegis CapitalUpgradesHoldBuy

View More Analyst Ratings for SVA
View the Latest Analyst Ratings

Posted-In: News Analyst Ratings

 

Related Articles (SVA)